Anavex Life Sciences (AVXL)
(Delayed Data from NSDQ)
$5.56 USD
+0.07 (1.28%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $5.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Anavex Life Sciences (AVXL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$43.00 | $46.00 | $40.00 | 683.24% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Anavex Life Sciences comes to $43.00. The forecasts range from a low of $40.00 to a high of $46.00. The average price target represents an increase of 683.24% from the last closing price of $5.49.
Analyst Price Targets (2 )
Broker Rating
Anavex Life Sciences currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on two recommendations.
Of the two recommendations deriving the current ABR, two are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 3 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/22/2024 | EF Hutton Financial | Jason Kolbert | Not Available | Strong Buy |
5/10/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 2 |
Average Target Price | $43.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 80 of 253 |
Current Quarter EPS Est: | -0.17 |
AVXL FAQs
Anavex Life Sciences Corp. (AVXL) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 2 brokerage firms.
The average price target for Anavex Life Sciences Corp. (AVXL) is $43.00. The current on short-term price targets is based on 1 reports.
The forecasts for Anavex Life Sciences Corp. (AVXL) range from a low of $40 to a high of $46. The average price target represents a increase of $673.38 from the last closing price of $5.56.
The current UPSIDE for Anavex Life Sciences Corp. (AVXL) is 673.38%
Based on short-term price targets offered by two analysts, the average price target for Anavex Life Sciences comes to $43.00. The forecasts range from a low of $40.00 to a high of $46.00. The average price target represents an increase of 683.24% from the last closing price of $5.49.